Lates News

Morgan Stanley released a report stating that its profit forecast for China National Pharmaceutical Group (Sinopharm) for the years 2025 to 2030 has been lowered by 1% to 6% due to a downward revision in sales forecasts for the medical devices and pharmaceutical distribution divisions. The bank has also lowered its target price from 23 Hong Kong dollars to 22.5 Hong Kong dollars and maintained a "hold" rating.